Sort   by:  
 Page size 
0
UnknownUnmet needs in the prediction and detection of metastases in prostate cancer.
Not available
S-EPMC3662846 | biostudies-literature
0
UnknownChemoprevention of prostate cancer with nutrients and supplements.
Not available
S-EPMC3097798 | biostudies-literature
0
UnknownDenosuma<b>b and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Not available
S-EPMC3795889 | biostudies-literature
0
UnknownNew and emerging therapies for <b>bone metastases in genitourinary cancers.
Not available
S-EPMC3661203 | biostudies-literature
0
UnknownMultiplex pyrosequencing assay using AdvISER-MH-PYRO algorithm: a case for rapid and cost-effective genotyping analysis of prostate cancer risk-associated SNPs.
Not available
S-EPMC4630960 | biostudies-literature
0
UnknownUnderstanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Not available
S-EPMC5301306 | biostudies-literature
0
UnknownThe Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.
Not available
S-EPMC8657254 | biostudies-literature
0
UnknownSkeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials.
Not available
S-EPMC5332552 | biostudies-literature
0
UnknownMatching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Not available
S-EPMC9271511 | biostudies-literature
0
UnknownConcurrent or layered treatment with radium-223 and enzalutamide or a<b>biraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Not available
S-EPMC7655504 | biostudies-literature
Sort   by:  
 Page size